Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222163 | 1.00 | POLB (0.63) | POLBMEN1KMT2ASMN1; SMN2DDB1 | |
| SCHEMBL10743630 | 0.86 | POLB (0.62) | POLBMEN1KMT2ASMN1; SMN2DDB1 | |
| SCHEMBL9530359 | 0.86 | POLB (0.62) | POLBMEN1KMT2ASMN1; SMN2DDB1 | |
| SCHEMBL13777929 | 0.84 | POLB (0.64) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL30597986 | 0.83 | NPSR1 (0.58) | POLBMEN1KMT2ASMN1; SMN2PARP1 | |
| SCHEMBL30434482 | 0.83 | POLB (0.55) | POLBMEN1KMT2ASMN1; SMN2PARP1 | |
| SCHEMBL2334270 | 0.83 | MEN1 (0.61) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL13777928 | 0.83 | NPSR1 (0.58) | POLBMEN1KMT2ASMN1; SMN2PARP1 | |
| SCHEMBL29549442 | 0.83 | MEN1 (0.61) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL28103666 | 0.83 | POLB (0.55) | POLBMEN1KMT2ASMN1; SMN2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3429996-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-109153644-A | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H·李·莫菲特癌症中心研究有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-8716520-B2 | Method of resolution of (RS)- 1,1′-BI-2-naphthol for obtaining enantiomeric pure I.E. (S)-(−)-1,1′-BI-2-naphthol and/or (R)-(+)-1,1′-BI-2-naphthol via co-crystal formation with optically active derivatives of γ-amino acids | LUPIN LIMITED (IN) | 2014-05-06 | — | — | US | disclosed |
| US-20120316361-A1 | METHOD OF RESOLUTION OF (RS)- 1,1'-BI-2-NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S)-(-)-1,1'-BI-2-NAPHTHOL AND/OR (R)-(+)-1,1'-BI-2-NAPHTHOL VIA CO-CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF y -AMINO ACIDS | LUPIN LIMITED (IN) | 2012-12-13 | — | — | US | disclosed |
| WO-2011086566-A1 | METHOD OF RESOLUTION OF (RS) - 1, 1 ' - BI - 2 - NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S) - (-) \" 1, 1 ' \"BI - 2 -NAPHTHOL AND/OR (R) - ( ) - 1, 1 ' - BI - 2 - NAPHTHOL VIA CO - CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF GAMMA -AMINO ACIDS | LUPIN LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316361-A1 | METHOD OF RESOLUTION OF (RS)- 1,1'-BI-2-NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S)-(-)-1,1'-BI-2-NAPHTHOL AND/OR (R)-(+)-1,1'-BI-2-NAPHTHOL VIA CO-CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF y -AMINO ACIDS | RRS1, RER1, QTRT1 | POLB 1375/4885MEN1 1947/4885KMT2A 4648/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | POLB 4576/4885MEN1 3857/4885KMT2A 3331/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | POLB 4464/4885MEN1 1005/4885KMT2A 3183/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | POLB 4402/4885MEN1 738/4885KMT2A 3074/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | POLB 4464/4885MEN1 1005/4885KMT2A 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.